Drug-device manufacturing change

A drug manufacturer of a cross-labeled combination product sought Chimera’s advice on how to report to an approved NDA the use of an improved device supplied by a new manufacturer. Chimera provided a regulatory strategy document to the pharmaceutical manufacturer outlining registration and labeling strategy options.